Department of Health
and Human Services (HHS)
and Human Services (HHS)
EXPIRED
February 22, 2021
NOT-EB-23-005 - Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health
NOT-NR-23-003 - Notice of NINR Participation in NOT-EB-21-001
NOT-EB-21-007 - Notice of Technical Assistance Webinar for Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health
PA-20-265 - PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
PA-20-261 - PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOT-AR-21-019 -Notice of NIAMS Participation in NOT-EB-21-001
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Minority Health and Health Disparities (NIMHD)
National Institute of Nursing Research ( NINR )
National Center for Advancing Translational Sciences (NCATS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases ( NIAMS )
Office of The Director, National Institutes of Health (OD)
All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.
Office of Research on Women's Health (ORWH)
The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering and participating Institutes and Centers (ICs) invite SBIR/STTR applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality (MMM).This NOSI is part of the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) initiative, which supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery.
Key Dates
|
Application Due Date(s) |
April 5, 2021, September 5, 2021, January 5, 2022, April 5, 2022, September 5, 2022, January 5, 2023, April 5, 2023, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
|
Scientific Merit Review |
July 2021, November 2021, March 2022, July 2022, November 2022, March 2023, and July 2023 |
|
Advisory Council Review |
August 2021, February 2022, June 2022, August 2022, February 2023, June 2023, and August 2023 |
|
Earliest Start Date |
December 2021, March 2022, July 2022, December 2022, March 2023, July 2023, and December 2023 |
|
Expiration Date |
April 6, 2023 |
Background
Rising rates of maternal morbidity and mortality constitute a serious health crisis in the U.S., with an estimated 700 maternal deaths each year from conditions related to or associated with pregnancy or childbirth and over 50,000 women experiencing severe maternal morbidity (SMM).To prevent the occurrence or advancement of diseases associated with pregnancy and to improve the health of pregnant and postpartum women, early identification of those who are at risk for MMM is needed. This identification of risk could be done in clinical settings to inform treatment and prevention approaches and/or in-home settings using continuous monitoring to alert clinicians or patients about potential risks and encourage prevention and treatment steps in real time.
Over the past few years, significant advances have been made in the discovery of biomarker signatures to identify risk for MMM, including those for biological and behavioral states related to disease prevention and identification. Many of these advances have been made because of the development of new and improved imaging, genetic, mobile, and machine learning technologies. Additionally, the development of devices that can measure such biomarkers at the point of care (POC) or in wearable fashion have become common place.
It now appears feasible to develop clinical tools that can measure biomarkers or surrogate markers for MMM. Such an objective tool would allow for improved clinical MMM research, prevention, and treatment. Currently, there is an urgent need for personalized treatment options for pregnant women at risk for MMM. However, MMM research and diagnosis are hampered due to the lack of technology to measure these objective predictors of risk for MMM in a POC or wearable continuous monitoring fashion for early detection. Quality research and treatment require quantitative measurement; these tools could improve the prevention and treatment of MMM.
Research Objectives
This NOSI is intended to encourage interest in the small business community to develop various approaches, technologies, and tools to address the health issues of maternal morbidity and mortality by achieving a wide array of outcomes, such as 1) the identification, phenotyping, subtyping, and stratification of patients at a greater risk of MMM, 2) multi-level interventions to address racial disparities in MMM, and 3) clinical decision-making that considers social and cultural biases.
Furthermore, this NOSI focuses on the development and validation of tools, technologies, and approaches, including artificial intelligence (AI) and machine learning, that indicate states of increased risk for and presence of MMM. This includes but is not limited to development of tools and technologies that:
Technologies that are affordable, scalable, and easy to implement within a variety of clinical settings, including primary care, will maximize the benefit to the patient population. Moreover, technologies that take social and cultural norms into the design consideration to maximize adoption by the patient population are of critical importance. These devices could be used at the point of care or in-home settings, where these devices could be worn by pre- and post-partum women and/or health-care providers when there is increasing risk. Due to the many recent advances in monitoring devices to predict health conditions by measuring behavioral and biomarkers, this NOSI is particularly interested in the development of new technologies that can combine different behavioral and biomarker measurements.
National Human Genome Research Institute (NHGRI)
NHGRI supports the development of resources, approaches, and technologies that accelerate and support studies focused on the structure and biology of genomes; the genomics of disease; the implementation and effectiveness of genomic medicine; genomic data science and bioinformatics; training, developing, and expanding the diversity of the genomics workforce; and ethical, legal, and social issues related to genomic advances. More details about the institute’s vision and priority areas can be found in the 2020 NHGRI Strategic Vision (https://www.genome.gov/2020SV).
Examples of research relevant to NHGRI’s mission include, but are not limited?to,?the following:?
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
The National Institute of Biomedical Imaging and Bioengineering (NIBIB)
NIBIB is interested in projects focused on the development, engineering and design of technologies that can monitor pre- and post-partum women for MMM factors.
Examples of research of interest to NIBIB include, but are not limited to:
A complete list of programmatic interests in NIBIB can be found at:https://www.nibib.nih.gov/research-funding.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
NOTE: For projects submitted to NIBIB proposing clinical trials, note that NIBIB will only support early-stage clinical trial applications, i.e., feasibility, Phase I, first-in-human, safety, or other small clinical trials, that inform early-stage technology development. This guidance applies to applications submitted using funding opportunity announcements (FOAs) listed in the Application and Submission Information section, and their subsequent reissuances. Under these announcements, NIBIB will not support applications proposing pivotal, Phase II, III, IV, or trials in which the primary outcome is efficacy, effectiveness, or a post-market concern.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NICHD is interested in projects focused on detecting, predicting, and/or monitoring conditions or disorders during pregnancy and/or the post-partum period that contribute to MMM. Examples of peri- and postpartum disorders and conditions of interests include, but are not limited to:
In addition to the above pregnancy-related or pregnancy-induced disorders, NICHD is also interested in projects that enhance the monitoring and management of women who enter pregnancy with existing medical conditions and risk factors for adverse pregnancy-related outcomes. Moreover, NICHD is interested in projects that include disadvantaged and underserved racial and ethnic populations, as well as populations with intellectual, developmental, and physical disabilities. The current NICHD Strategic Plan can be found at: https://www.nichd.nih.gov/about/org/strategicplan
NOTE: For applications submitted to this, NICHD will support those that propose clinical trials.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Heart, Lung, and Blood Institute (NHLBI)
NHLBI is interested in projects focused on detecting, predicting, and/or monitoring heart, lung, blood, and sleep-related (HLBS) disorders during pregnancy and/or the post-partum period. Examples of peri- and postpartum disorders and conditions of interest to NHLBI include, but are not limited to:
In addition to the above pregnancy-related or pregnancy-induced disorders, the NHLBI is also interested in projects that enhance the monitoring and management of women with existing HLBS-specific disorders and risk factors who enter pregnancy or are considering becoming pregnant. Technologies that take social and cultural norms into design consideration to maximize their adoption are also encouraged. NHLBI also encourages dissemination and implementation projects that address barriers to uptake of evidence-based practices for HLBS conditions and disorders. A complete list of scientific focus areas in the NHLBI can be found at: https://www.nhlbi.nih.gov/science.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Institute of Mental Health (NIMH)
NIMH’s mission is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. For this NOSI, NIMH is interested in supporting the development of technologies that can predict, detect, monitor, prevent, and/or treat perinatal depression and associated psychiatric morbidity (e.g., bipolar disorder, perinatal psychosis, self-harm and suicide attempts) in individual patients and can alert patients and clinicians in near-real time.
Examples of research of interest to NIMH include, but are not limited to:
Applications submitted to NIMH that involve a clinical trial (CT) should comport with NIMH CT expectations, including utilization of an experimental therapeutics approach for the development and testing of therapeutic, preventive, and services interventions. For more information on mechanistic, treatment, prevention or services CTs at NIMH see: https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml. Prospective applicants are strongly encouraged to contact NIMH prior to submission.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Center for Advancing Translational Sciences (NCATS)
NCATS is interested in projects focused on bioinformatics and clinical research management tools and technologies that address pre- and post-partum factors related to MMM.
Examples of research of interest to NCATS include, but are not limited to:
A complete list of programmatic interests can be found at:https://ncats.nih.gov/smallbusiness/priorities
NOTE: For applications submitted to this NOSI that propose clinical trials, NCATS does not support applications proposing any clinical trials in the submitted application. Applicants are encouraged to contact NCATS staff at [email protected] prior to submitting their application in order to ensure it is aligned with NCATS’s SBIR/STTR research interests.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Institute of Neurological Disorders and Stroke (NINDS)
The mission of NINDS is to reduce the burden of neurological disease a burden borne by every age group, by every segment of society, by people all over the world (https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). To this end, the Institute supports and conducts research on the healthy and diseased brain, spinal cord, and peripheral nerves. For this NOSI, NINDS is interested in the development of technologies that address maternal morbidity and mortality (MMM) within the scope of the NINDS mission space. Potential NINDS areas of interest related to maternal mortality and morbidity include stroke, cerebral venous thrombosis (CVT), migraine, peripheral neuropathies, chorea, and posterior reversible encephalopathy syndrome (PRES).
NOTE: NINDS does not support applications to the omnibus clinical trial PAR-20-261 or PAR-20-262. Small Business concerns proposing clinical trials under the NINDS mission space should consider applying directly to PAR-18-617: NINDS Exploratory Clinical Trials for Small Business (R42), or PAR-18-618 NINDS Exploratory Clinical Trials for Small Business (R44). In addition, applicants are encouraged to consider Small Business U44 Cooperative Agreement mechanisms under the NINDS Translational Neural Devices program https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research/Funding-Programs-Researchers/Translational-Devices.
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R42 |
PAR-18-617- NINDS Exploratory Clinical Trials for Small Business (R42 Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R44 |
PAR-18-618- NINDS Exploratory Clinical Trials for Small Business (R44 Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Institute on Minority Health and Health Disparities (NIMHD)
NIMHD has an ongoing interest in technological innovations to improve health and to reduce, eliminate or prevent disparities in maternal mortality and morbidity experienced by racial and ethnic minority women compared to white women. When developing new technologies, including artificial intelligence and machine learning, the diverse voices of underserved women need to be included to mitigate unintended consequences and prevent exacerbation of disparities. The health of racial and ethnic minority women and the excess burden of maternal mortality and morbidity experienced result from factors operating within and across multiple domains (e.g., biological, behavioral, socio-cultural, environmental, physical environment, healthcare system) and multiple levels (e.g., individual, interpersonal, community, societal) (see the NIMHD Research Framework).
Projects leading to commercially available, affordable, accessible and culturally acceptable technologies disrupting or preventing the interactions and processes responsible for or implicated in the creating, promoting or sustaining these and associated disparities are encouraged. Projects examining social determinants of health and informed by the NIMHD Research Framework are encouraged. Projects that leverage the capabilities of design thinking or similar systems or societal level thinking are encouraged. Projects employing teams with expertise across two or more domains are also encouraged.
Examples of potential topic areas include but are not limited to:
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
National Institute of Allergy and Infectious Diseases (NIAID)
NIAID supports basic and translational research to better understand, diagnose, prevent, and treat, infectious and immune-mediated diseases, including diseases that impact the health of women and girls. NIAID is interested in small business technological innovations that address maternal morbidity and mortality within the scope of the NIAID mission. Examples include, but are not limited to:
|
Activity Code |
FOA |
First Available Due Date |
|
R41, R42 |
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R41, R42 |
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
April 5, 2021 |
|
R43, R44 |
PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
April 5, 2021 |
|
R43, R44 |
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
April 5, 2021 |
|
R41, R42, R43, R44 |
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) |
Due dates may vary by awarding IC. See the awarding IC's web site. Applicants may also contact their respective awarding IC. |
Office of Research on Women’s Health (ORWH)
ORWH focuses on research that is relevant to the health of women and is interested in small business innovations that intersect with the goals, objectives, and guiding principles of the trans-NIH Strategic Plan for Women’s Health Research (https://orwh.od.nih.gov/about/trans-nih-strategic-plan-womens-health-research) and maternal health. Specific examples include, but are not limited to the development of technologies that can improve maternal health in:
Application and Submission Information
This notice applies to due dates on or after April 5, 2021 and subsequent receipt dates through April 5, 2023.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this NOSI.
PA-20-265- PHS-2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
PA-20-261- PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
PA-20-260- PHS 2020 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications ([R43/R44] Clinical Trial Not Allowed)
PA-20-262 PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) Applications for this administrative supplement will only be accepted for R41, R42, R43, R44 grant mechanisms.
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
For funding consideration, applicants must include NOT-EB-21-001 in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applicants planning to apply in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with an NIH Program Officer listed on this NOSI well in advance of the application due date.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Scientific/Research Contacts
Ilana Goldberg, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-402-3465
Email:[email protected]
Jamie White, M.S.
Office Of Research On Women's Health (ORWH)
Phone:301-402-1770
E-mail: [email protected]
Andrew A. Bremer, M.D., Ph.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD
Telephone: 301-402-7886
Email:[email protected]
Adam J. Haim, Ph.D.
Division of Services and Intervention Research
National Institute of Mental Health (NIMH)
Phone: (301) 435-3593
Email: [email protected]
Jyoti Dayal, M.S.
National Human Genome Research Institute (NHGRI)
Telephone: 301-480-2307
Email: [email protected]
Emily Caporello, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 301-496-1779
Email: [email protected]
Jasmina Varagic, M.D., Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Phone: 301-827-5569
Email: [email protected]
Krishna Balakrishnan, PhD, MBA
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-7149
Email:[email protected]
Soju Chang, MD, MPH
National Center for Advancing Translational Sciences (NCATS)
Telephone: (301) 827-9206
E-mail: [email protected]
Deborah Linares
National Institute on Minority and Health and Health Disparities (NIMHD)
Telephone: (301) 402-2516
Email: [email protected]
Mercy R Prabhudas
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 240-627-3534
E-mail: [email protected]
Peer Review Contact(s)
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Financial/Grants Management Contact(s)
James Huff
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-4786
Email: [email protected]
Monika Christman
National Human Genome Research Institute (NHGRI)
Phone: 301-435-7860
Ann Marie Brasile Mejac
National Heart, Lung, And Blood Institute (NHLBI)
Phone: (301) 827-8016
E-mail:[email protected]
Jason A Lundgren
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 240-669-2973
E-mail:[email protected]
Melani Ledu
Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD)
Phone: 301-402-4165
E-mail: [email protected]
Jane Lin
National Institute of Mental Health (NIMH)
Telephone: 301-443-2229
Email:[email protected]
Priscilla Grant, JD
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-594-8412
E-mail: [email protected]
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email:[email protected]